Resolution of recurrent hepatitis B in two liver transplant recipients treated with famciclovir

Steven Huy Han; Milan Kinkhabwala; Paul Martin; Curtis Holt; Natalie Murray; Philip Seu; Steven Rudich; D. Hiserodt; David Imagawa; Ronald W. Busuttil

doi:10.1111/j.1572-0241.1998.00626.x

Resolution of recurrent hepatitis B in two liver transplant recipients treated with famciclovir

Steven Huy Han, Milan Kinkhabwala, Paul Martin, Curtis Holt, Natalie Murray, Philip Seu, Steven Rudich, D. Hiserodt, David Imagawa, Ronald W. Busuttil

Research output: Contribution to journal › Article › peer-review

Abstract

Recurrent hepatitis B infection after orthotopic liver transplantation remains problematic despite prophylaxis with hepatitis B immune globulin (anti-HBs IgG). Recently, famciclovir (an oral nucleoside analog) has been shown to have potent antiviral activity against hepatitis B in vitro as well as in patients with chronic hepatitis B. We present two patients who developed recurrent hepatitis B after orthotopic liver transplantation and were treated with famciclovir, 500 mg t.i.d. Both patients subsequently responded with marked improvement in biochemical liver tests and histology, with subsequent loss of hepatitis B surface antigen. Famciclovir is a useful agent in the treatment of hepatitis B in the liver transplant recipient.

Original language	English (US)
Pages (from-to)	2245-2247
Number of pages	3
Journal	American Journal of Gastroenterology
Volume	93
Issue number	11
DOIs	https://doi.org/10.1111/j.1572-0241.1998.00626.x
State	Published - Nov 1 1998
Externally published	Yes

ASJC Scopus subject areas

Hepatology
Gastroenterology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/j.1572-0241.1998.00626.x

Cite this

@article{d04d192c0b3845baa8e16dabd7ec2c4d,

title = "Resolution of recurrent hepatitis B in two liver transplant recipients treated with famciclovir",

abstract = "Recurrent hepatitis B infection after orthotopic liver transplantation remains problematic despite prophylaxis with hepatitis B immune globulin (anti-HBs IgG). Recently, famciclovir (an oral nucleoside analog) has been shown to have potent antiviral activity against hepatitis B in vitro as well as in patients with chronic hepatitis B. We present two patients who developed recurrent hepatitis B after orthotopic liver transplantation and were treated with famciclovir, 500 mg t.i.d. Both patients subsequently responded with marked improvement in biochemical liver tests and histology, with subsequent loss of hepatitis B surface antigen. Famciclovir is a useful agent in the treatment of hepatitis B in the liver transplant recipient.",

author = "Han, {Steven Huy} and Milan Kinkhabwala and Paul Martin and Curtis Holt and Natalie Murray and Philip Seu and Steven Rudich and D. Hiserodt and David Imagawa and Busuttil, {Ronald W.}",

year = "1998",

month = nov,

day = "1",

doi = "10.1111/j.1572-0241.1998.00626.x",

language = "English (US)",

volume = "93",

pages = "2245--2247",

journal = "American Journal of Gastroenterology",

issn = "0002-9270",

publisher = "Nature Publishing Group",

number = "11",

}

TY - JOUR

T1 - Resolution of recurrent hepatitis B in two liver transplant recipients treated with famciclovir

AU - Han, Steven Huy

AU - Kinkhabwala, Milan

AU - Martin, Paul

AU - Holt, Curtis

AU - Murray, Natalie

AU - Seu, Philip

AU - Rudich, Steven

AU - Hiserodt, D.

AU - Imagawa, David

AU - Busuttil, Ronald W.

PY - 1998/11/1

Y1 - 1998/11/1

N2 - Recurrent hepatitis B infection after orthotopic liver transplantation remains problematic despite prophylaxis with hepatitis B immune globulin (anti-HBs IgG). Recently, famciclovir (an oral nucleoside analog) has been shown to have potent antiviral activity against hepatitis B in vitro as well as in patients with chronic hepatitis B. We present two patients who developed recurrent hepatitis B after orthotopic liver transplantation and were treated with famciclovir, 500 mg t.i.d. Both patients subsequently responded with marked improvement in biochemical liver tests and histology, with subsequent loss of hepatitis B surface antigen. Famciclovir is a useful agent in the treatment of hepatitis B in the liver transplant recipient.

AB - Recurrent hepatitis B infection after orthotopic liver transplantation remains problematic despite prophylaxis with hepatitis B immune globulin (anti-HBs IgG). Recently, famciclovir (an oral nucleoside analog) has been shown to have potent antiviral activity against hepatitis B in vitro as well as in patients with chronic hepatitis B. We present two patients who developed recurrent hepatitis B after orthotopic liver transplantation and were treated with famciclovir, 500 mg t.i.d. Both patients subsequently responded with marked improvement in biochemical liver tests and histology, with subsequent loss of hepatitis B surface antigen. Famciclovir is a useful agent in the treatment of hepatitis B in the liver transplant recipient.

UR - http://www.scopus.com/inward/record.url?scp=0032451391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032451391&partnerID=8YFLogxK

U2 - 10.1111/j.1572-0241.1998.00626.x

DO - 10.1111/j.1572-0241.1998.00626.x

M3 - Article

C2 - 9820407

AN - SCOPUS:0032451391

SN - 0002-9270

VL - 93

SP - 2245

EP - 2247

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

IS - 11

ER -

Resolution of recurrent hepatitis B in two liver transplant recipients treated with famciclovir

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this